相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。External control arms in oncology: current use and future directions
P. S. Mishra-Kalyani et al.
ANNALS OF ONCOLOGY (2022)
The molecular characteristics of high-grade gastroenteropancreatic neuroendocrine neoplasms
Andreas Venizelos et al.
ENDOCRINE-RELATED CANCER (2022)
Final overall survival results from the NICE-NEC trial (GETNE-T1913): A phase II study of nivolumab and platinum-doublet chemotherapy (CT) in untreated advanced G3 neuroendocrine neoplasms (NENs) of gastroenteropancreatic (GEP) or unknown (UK) origin
M. C. Riesco Martinez et al.
ANNALS OF ONCOLOGY (2022)
Second-line treatment and prognostic factors in neuroendocrine carcinoma: the RBNEC study
Julien Hadoux et al.
ENDOCRINE-RELATED CANCER (2022)
ctDNA in Neuroendocrine Carcinoma of Gastroenteropancreatic Origin or of Unknown Primary: The CIRCAN-NEC Pilot Study
Laura Gerard et al.
NEUROENDOCRINOLOGY (2021)
FOLFIRINEC: a randomized phase II trial of mFOLFIRINOX vs platinum-etoposide for metastatic neuroendocrine carcinoma of gastroenteropancreatic or unknown origin
Julien Hadoux et al.
DIGESTIVE AND LIVER DISEASE (2021)
Etoposide and cisplatin versus irinotecan and cisplatin as the first-line therapy for patients with advanced, poorly differentiated gastroenteropancreatic neuroendocrine carcinoma: A randomized phase 2 study
Panpan Zhang et al.
CANCER (2020)
Extrapulmonary poorly differentiated NECs, including molecular and immune aspects
Mairead G. McNamara et al.
ENDOCRINE-RELATED CANCER (2020)
Randomised phase II trial of CAPTEM or FOLFIRI as SEcond-line therapy in NEuroendocrine CArcinomas and exploratory analysis of predictive role of PET/CT imaging and biological markers (SENECA trial): a study protocol
Alberto Bongiovanni et al.
BMJ OPEN (2020)
Second-line treatment in patients with advanced extra-pulmonary poorly differentiated neuroendocrine carcinoma: a systematic review and meta-analysis
Mairead G. McNamara et al.
THERAPEUTIC ADVANCES IN MEDICAL ONCOLOGY (2020)
Evaluating bevacizumab in combination with FOLFIRI after the failure of platinum-etoposide regimen in patients with advanced poorly differentiated neuroendocrine carcinoma: The PRODIGE 41-BEVANEC randomized phase II study
Thomas Walter et al.
DIGESTIVE AND LIVER DISEASE (2018)
Bevacizumab-based Chemotherapy for Poorly-differentiated Neuroendocrine Tumors
Thomas Collot et al.
ANTICANCER RESEARCH (2018)
Poorly differentiated gastro-entero-pancreatic neuroendocrine carcinomas: Are they really heterogeneous? Insights from the FFCD-GTE national cohort
T. Walter et al.
EUROPEAN JOURNAL OF CANCER (2017)
Design and Validation of the GI-NEC Score to Prognosticate Overall Survival in Patients With High-Grade Gastrointestinal Neuroendocrine Carcinomas
Angela Lamarca et al.
JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE (2017)
Design and Validation of the GI-NEC Score to Prognosticate Overall Survival in Patients With High-Grade Gastrointestinal Neuroendocrine Carcinomas
Angela Lamarca et al.
JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE (2017)
Trends in the Incidence, Prevalence, and Survival Outcomes in Patients With Neuroendocrine Tumors in the United States
Arvind Dasari et al.
JAMA ONCOLOGY (2017)
Efficacy of topotecan in pretreated metastatic poorly differentiated extrapulmonary neuroendocrine carcinoma
Leonidas Apostolidis et al.
CANCER MEDICINE (2016)
Gastroenteropancreatic High-Grade Neuroendocrine Carcinoma
Halfdan Sorbye et al.
CANCER (2014)
Bevacizumab combined with 5-FU/streptozocin in patients with progressive metastatic well-differentiated pancreatic endocrine tumours (BETTER trial) - A phase II non-randomised trial
Michel Ducreux et al.
EUROPEAN JOURNAL OF CANCER (2014)
Bevacizumab plus capecitabine in patients with progressive advanced well-differentiated neuroendocrine tumors of the gastro-intestinal (GI-NETs) tract (BETTER trial) - A phase II non-randomised trial
Emmanuel Mitry et al.
EUROPEAN JOURNAL OF CANCER (2014)
FOLFIRI plus cetuximab versus FOLFIRI plus bevacizumab as first-line treatment for patients with metastatic colorectal cancer (FIRE-3): a randomised, open-label, phase 3 trial
Volker Heinemann et al.
LANCET ONCOLOGY (2014)
Angiogenesis in Neuroendocrine Tumors: Therapeutic Applications
Jean-Yves Scoazec
NEUROENDOCRINOLOGY (2013)
FOLFIRI regimen: an effective second-line chemotherapy after failure of etoposide-platinum combination in patients with neuroendocrine carcinomas grade 3
O. Hentic et al.
ENDOCRINE-RELATED CANCER (2012)
Response to temozolomide and bevacizumab in a patient with poorly differentiated neuroendocrine carcinoma
Daniel P. Lindholm et al.
MEDICAL ONCOLOGY (2012)
Quality of Clinical Trials in Gastroenteropancreatic Neuroendocrine Tumours
Thomas Walter et al.
NEUROENDOCRINOLOGY (2012)
Future Directions in the Treatment of Neuroendocrine Tumors: Consensus Report of the National Cancer Institute Neuroendocrine Tumor Clinical Trials Planning Meeting
Matthew H. Kulke et al.
JOURNAL OF CLINICAL ONCOLOGY (2011)
A Case of High-Grade Neuroendocrine Carcinoma That Improved with Bevacizumab plus Modified FOLFOX6 as the Fourth-Line Chemotherapy
Satoshi Takeuchi et al.
CASE REPORTS IN ONCOLOGY (2011)
分享论文
